• Dr. John Patton is recognized as a Leader in the Inhaled Formulation Solutions To Bring Industry Expertise To Innovative, Research-Based Pharmaceutical Firm

Toronto, Ontario--(Newsfile Corp. - March 1, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a range of leading-edge and proprietary diagnostic and medical technologies, is pleased to announce that Dr. John Patton has joined as Chairman of InStatin Inc.("InStatin") . InStatin is a privately-held innovative, research-based pharmaceutical company specializing in inhaled therapies, which is a recent Therma Bright investment.

Dr. John Patton is one of the leading industry pioneers in the development of inhaled drugs. He recently served as Executive Chairman and Co-Founder of iPharma Labs, an International Contract Development Research Organization (CDRO) dedicated to developing the best inhalation delivery products in the world, which was acquired by Kindeva Drug Delivery in June 2022.

Prior to joining InStatin, John served in senior leadership roles and on the Board of Directors within the space, most notably he was the co-founder of Inhale/Nektar (NKTR) in 1990. Inhale/Nektar (NKTR) achieved a US $2.1bn valuation on NASDAQ. The Company received global approval of its' inhaled insulin solution with Pfizer, which was recognized by the Wall Street Journal as the 2006 Medical Innovation of the Year. Furthermore, John was a founding investor of Halozyme (HALO) in 1999 and served on the Company's board director until 2015. In 2006, Halozyme (HALO) was recognized as one of the top biotech stock in California and has a current market valuation of ~US $6.5bn.

In addition to iPharma, Inhale/Nektar and Halozyme, John's other successes include being the Founder and CEO of Dance Biopharm (now Aerami Therapeutics) (2009-2018) - a 3rd generation inhaled insulin phase 3 ready solution and Co-founder of InCarda Therapeutics - a developer of inhaled medicines for acute cardiac conditions. Furthermore, John has received numerous honours and awards throughout his career, and has been published in over 100+ publications and has more than 45 patents to his name.

"I'm thrilled to work with Dr. Patton as part of the InStatin team," shared Rob Fia, CEO of Therma Bright, which invested in InStatin's innovative and novel inhaled statins treatment for patients with chronic lung conditions. "Dr. Patton brings a great deal of experience building multibillion-dollar pharmaceutical solution companies within the inhaled formulation space, and we believe his experience and contributions will have great impact on the future success."

Dr. Patton will assume his role with InStatin immediately and will begin working with the management team on the 2023 and long-term plan.

About InStatin

InStatin is developing novel treatments using inhaled statins for the treatment and management of patients with chronic lung conditions such as asthma and chronic obstructive pulmonary disease ("COPD"). For additional information visit www.instatininc.com.

About Therma Bright Inc.

Therma Bright, is a developer and partner in a range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright is the developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test, currently undergoing regulatory review. Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.

Therma Bright Inc.
Rob Fia, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on Twitter

FORWARD-LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as development and commercialization of a rapid COVID-19 viral assay and related instrumentation. as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.